هلدینگ پانیدکو با مشارکت افراد با تجربه در صنایع بزرگ کشور تشکیل گردیده و استراتژی خود را بر مبنای سرمایه گذاری در صنایع مختلف کشور ، از جمله صنایع خودرو سازی قرار داده است .
تامین قطعات و مجموعه های با کیفیت و مطمئن جهت برآورده نمودن نیازهای صنایع خودرو سازی و حمل و نقل و بازار خدمات پس از فروش آنها جزو اقدامات اولیه این هلدینگ تعریف گردیده است.
برخی از صاحبان سهام هلدینگ پانیدکو ، خود صاحب شرکت و کارگاههای ساخت و تولید در زمینه های محتلف میباشند که ظرفیت کارگاههای خود را در اختیار هلدینگ قرار داده اند.

آدرس: تهران ، فلکه دوم صادقیه ، برج گلدیس، طبقه هفتم، واحد 721

تلفن: 021xxxxxxxx

ایمیل: info[at]panid-co.ir

کد پستی: 1234567890

Aronow3 step 1 Carvell Health Properties, Inc, Cheltenham, PA 19012, United states of america

Aronow3 step 1 Carvell Health Properties, Inc, Cheltenham, PA 19012, United states of america

Aronow3 step 1 Carvell Health Properties, Inc, Cheltenham, PA 19012, United states of america

Unformatted text message preview: Shamliyan et al. Watercraft Including 2020;4:35 DOI: 7/2574- Ship And Medical Comment Unlock Access Lack of proof regarding advantages from sodium-sugar cotransporter-dos inhibitors in heart incapacity which have kept ejection tiny fraction Tatyana A beneficial. Shamliyan1, Anna A beneficial. Avanesova2, Wilbert S. North-Caucasus Federal University, Stavropol 355000, Russian Federation. Tatyana A beneficial. Shamliyan, Carvell Wellness Properties, Inc, Cheltenham, PA 19012, U . s .. E-mail: [email protected] Simple tips to cite this particular article: Shamliyan TA, Avanesova AA, Aronow WS. Lack of research from benefits from sodiumglucose cotransporter-dos inhibitors into the cardiovascular system failure which have managed ejection fraction. Motorboat And additionally 2020;4:35. Received: Accepted: Instructional Publisher: Ryuuichi Morishita Content Editor: Cai-Hong Wang Manufacturing Editor: Jing Yu Abstract Aim: Sodium-glucose cotransporter-dos (SGLT2)-inhibitors improve survival from inside the adults with reduced ejection small fraction.

Motorboat As well as 2020;4:thirty five We regardless of center failure variety of, few situations, and you will probable publication bias hampered the grade of evidence

Health-related consequences inside adults that have center inability (HF) with managed ejection fraction (HFpEF) haven’t been methodically analyzed. Methods: We used a systematic quick literary works comment and you can appraised the quality of proof with the Leveling regarding Suggestions Review, Innovation and you will Analysis methodology. Results: I known blog post-hoc subgroup analyses out of four Downey escort service randomized regulated clinical trials (RCTs) and you can unpublished results from 2 RCTs. In two RCTs vs . Dapagliflozin or ertugliflozin did not improve all the-end in or aerobic passing or hospitalization to have HF during the grownups that have HF and you can LVEF > 45% in two crucial RCTs versus . Empagliflozin failed to raise do it element, patient-stated consequences or congestion, diuretic use as well as-trigger health care funding utilization in unpublished RCT vs . Various significance out of HFpEF, post-hoc communications analyses indicating consequences improvement © The author(s) 2020.

Upcoming look should employ uniform significance of HFpEF and you can look at the outcomes off SGLT2- Inhibitors from inside the patients with different HFpEF phenotypes and you may fundamental grounds

Discover Supply This information is authorized below a creative Commons Attribution cuatro. Webpage dos of 13 Shamliyan ainsi que al. Conclusion: Existing evidence is decreased to support decisive logical suggestions for fool around with off SGLT2inhibitors inside people which have HFpEF. Keywords: Sodium-sugar cotransporter-dos – inhibitors, heart incapacity that have preserved ejection small fraction, cardiovascular mortality, heart failure hospitalization, systematic literary works feedback, grading of recommendations evaluation, creativity and you can analysis methods Introduction Center incapacity that have preserved ejection tiny fraction (HFpEF) gifts a serious and you can increasing logical and you can financial load in the aging populations, especially with prevalent arterial blood pressure and you can diabetic issues[1-4].

Projected step 1-12 months all the-end in death costs away from 33% and all sorts of cause readmission rates away from 67% from inside the customers having HFpEF haven’t improve over the last years in america. Diabetes are a more popular exposure grounds to possess aerobic morbidity and you can mortality[5,6]. Even when growing services increased aerobic outcomes for the individuals with diabetes[eight,8], no services have been shown to boost endurance and reduce health care and attention use within people who have HFpEF[9-14]. Sodium-sugar cotransporter-2 (SGLT2)- inhibitors are observed to change survival when you look at the center failure which have treat ejection small fraction and relieve the risk of big cardiovascular events and center failure hospitalizations when you look at the grownups having diabetes[15-19]. Present facts-mainly based direction highly recommend SGLT2- inhibitors towards improvement in cardio outcomes inside the adults having sort of 2 diabetes[26-29]. Although not, the data regarding the advantages from SGLT2- inhibitors in grownups that have HFpEF hasn’t been systematically examined and appraised.

I presented a scientific quick literature writeup on the complete and you can ongoing clinical studies intended for patient consequences in adults having HFpEF. Steps I used our very own comment depending on the arranged priori method[30-32]. We hypothesized one SGLT2inhibitors boost cardiovascular death, morbidity and you will hospitalizations into the people that have HFpEF, that have or instead diabetic issues[33-38]. Qualified treatments incorporated SGLT2- inhibitors no matter what country’ recognition [Supplementary Table step 1] emphasizing this new availability in the usa, for example dapagliflozin, canagliflozin, empagliflozin and you can ertugliflozin [Secondary Dining table dos]. I provided education you to definitely compared SGLT2- inhibitors having antidiabetic medications otherwise placebo. I abstracted claimed number of events or prices of all-end in and you will cardiovascular mortality, incident or progressing off cardio incapacity, and you may hospitalizations getting heart failure[14,39]. I including checked-out the new advertised intermediate consequences, e.

startitt
بدون نظر

ارسال یک نظر

نظر
نام
ایمیل
وبسایت